LRP5 and breast cancer: Using inhibitors that prevent activation of the FRP-LRP5/6 receptor in a mouse mammary tumor-derived cell line, we demonstrated that elevated Wnt gene expression leads to autocrine activation of the Wnt/β-catenin pathway (Fig. 1).